The finding of this study suggest the introduction of combined
therapy of CVA1020 (vancomycin with L-arginine and ceftriaxone)
for the treatment of MRSA and hGISA is a suitable
alternative to curb growing gram positive resistance where
acquisition and spread of MRSA and hGISA among S. aureus
constitute a major threat in the modern medicine.